Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
Ahmad G. Alzahrani/LinkedIn
Nov 15, 2026, 16:14

Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal

Ahmad G. Alzahrani, Consultant in Internal Medicine, shared a post on LinkedIn:

”Major Bleeding and Anticoagulant Reversal | The 3 AM Clinical Decision Guide

When a patient on anticoagulation develops major bleeding, every minute matters.

The challenge is not simply stopping the anticoagulant — it is controlling the bleeding while minimizing the risk of recurrent thrombosis.

First: Stabilize the patient

  • Assess hemodynamic stability and bleeding severity.
  • Hold anticoagulation and initiate resuscitation.
  • Identify and control the bleeding source.

Know your reversal strategy:

  • Warfarin: 4-factor PCC + IV vitamin K.
  • Dabigatran: Idarucizumab.
  • Apixaban/Rivaroxaban: Consider 4-factor PCC according to current local protocols.
  • UFH: Protamine.
  • LMWH: Protamine provides partial reversal.

Not every bleed requires reversal. The decision depends on bleeding severity, anticoagulant exposure, and clinical context.

And remember: Reversal is only half the decision.

Once hemostasis is achieved, reassess the indication for anticoagulation, thrombotic risk, and the safest time to restart treatment.

The 3 AM takeaway:

Stabilize, Then Control the Source, Then Reverse When Indicated, and Finally Plan the Restart.

References: ACC Expert Consensus Decision Pathway (2020) | ISTH SSC Guidance (2024) | Thrombosis Canada Clinical Guides.”

Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal

Stay updated with Hemostasis Today.

Ahmad G. Alzahrani Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine
NewsFeed